XGEVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XGEVA (XGEVA).
Monoclonal antibody that binds to RANKL, inhibits osteoclast formation, function, and survival, decreasing bone resorption and increasing bone density.
| Metabolism | Denosumab is a monoclonal antibody; metabolism is typical of IgG antibodies, primarily via catabolic pathways. No specific metabolic enzymes or CYP450 involvement. |
| Excretion | Primarily cleared via reticuloendothelial system; minimal renal elimination (<5% unchanged in urine); no significant biliary or fecal excretion. |
| Half-life | Terminal elimination half-life is approximately 32 days (range 25-50 days) following subcutaneous administration; this supports monthly dosing for sustained bone turnover suppression. |
| Protein binding | Binds to plasma proteins, primarily to RANKL; no specific carrier proteins; overall binding is high (estimated >99%) due to target-mediated disposition. |
| Volume of Distribution | Volume of distribution is approximately 0.15 L/kg (3.7 L for a 70 kg individual), indicating limited extravascular distribution and primarily intravascular space. |
| Bioavailability | Subcutaneous: Bioavailability is approximately 62% relative to intravenous administration, with peak concentrations achieved 3-7 days post-dose. |
| Onset of Action | Subcutaneous: Suppression of bone resorption (decrease in urinary NTX) is observed within 24 hours, with maximal reduction by day 3. |
| Duration of Action | After a single subcutaneous dose, bone resorption markers remain suppressed for up to 6 months; clinical effect persists with monthly dosing. |
120 mg subcutaneously once every 4 weeks. Administer as a single dose; do not split the dose. Administer calcium and vitamin D supplementation as necessary.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required based on GFR, including patients with severe renal impairment (CrCl <30 mL/min) and on dialysis. However, monitor calcium levels and supplement accordingly. |
| Liver impairment | No dose adjustment required for hepatic impairment per Child-Pugh classification; safety and efficacy in severe hepatic impairment not established, use with caution. |
| Pediatric use | Not approved for use in pediatric patients due to risk of osteosarcoma; no pediatric dosing guidelines available. |
| Geriatric use | No specific dose adjustment in elderly patients; clinical studies included subjects aged ≥65 years with no overall differences in safety or efficacy. Consider renal function and calcium homeostasis monitoring. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XGEVA (XGEVA).
| Breastfeeding | It is unknown if denosumab is excreted in human breast milk. Monoclonal antibodies (IgG) are known to be present in human milk, but the M/P ratio has not been determined for denosumab. Because of the potential for serious adverse reactions in the nursing infant (e.g., bone growth inhibition), breastfeeding is not recommended during treatment and for at least 5 half-lives (approximately 5 months) after the last dose. The drug is a large protein, likely degraded in the infant gastrointestinal tract, but systemic absorption is possible. |
| Teratogenic Risk | XGEVA (denosumab) is a RANKL inhibitor. Monoclonal antibodies are transported across the placenta in a linear manner as pregnancy progresses, with the largest amount transferred during the third trimester. Fetal exposure may lead to inhibition of RANKL signaling, which is critical for fetal bone development and lymph node formation. Animal studies (cynomolgus monkeys) have shown increased neonatal mortality, abnormal bone growth, and reduced lymph node development when administered during pregnancy. Based on mechanism of action and animal data, XGEVA may cause fetal harm if administered to pregnant women. There are no adequate human studies. First trimester risk: minimal monoclonal antibody transfer, but data limited. Second and third trimesters: increasing risk of fetal bone abnormalities (e.g., osteopetrosis) and developmental delays. |
■ FDA Black Box Warning
Warning: Denosumab (Xgeva) can cause severe symptomatic hypocalcemia, which can be fatal. Pre-existing hypocalcemia must be corrected prior to initiating therapy. Monitor calcium levels regularly, especially in patients with renal impairment. Advise patients to seek medical attention for symptoms of hypocalcemia such as muscle spasms, twitches, or cramps.
| Common Effects | Musculoskeletal bone muscle or joint pain Pain in extremities Nerve pain Constipation Rash Urinary tract infection |
| Serious Effects |
["Hypersensitivity to denosumab or any component of the formulation","Pre-existing hypocalcemia (must be corrected before use)"]
| Precautions | ["Hypocalcemia: Correct pre-existing hypocalcemia prior to therapy; monitor calcium levels, especially in first weeks and in renal impairment","Osteonecrosis of the jaw (ONJ): Risk with invasive dental procedures; perform dental exam prior to therapy and avoid during treatment","Atypical femur fractures: Discontinue therapy if suspected; stress fractures may occur","Serious infections: Increased risk due to immunosuppression; monitor for signs of infection","Dermatologic reactions: Severe skin reactions reported; discontinue if severe","Fetal harm: Can cause fetal harm; advise females of reproductive potential to use contraception during and for 5 months after last dose","Renal impairment: Monitor calcium more frequently in patients with CrCl < 30 mL/min or on dialysis","Multiple vertebral fractures after discontinuation: Risk of fractures increases after stopping; transition to other antiresorptive therapy if treatment discontinued"] |
Loading safety data…
| Fetal Monitoring | If XGEVA is used during pregnancy, monitor fetal bone development via ultrasound (femur length, mineralization) and consider serial fetal growth scans. In the mother, monitor serum calcium frequently (especially in first 2 weeks of each dose) due to risk of severe hypocalcemia; correct pre-existing hypocalcemia before initiation. Also monitor renal function and phosphate levels. Postnatally, assess infant for hypocalcemia, bone demineralization, and immunologic dysfunction (lymph node development). |
| Fertility Effects | Based on animal studies, XGEVA may impair fertility. In female cynomolgus monkeys, denosumab caused dose-dependent decreases in ovarian function (follicular development, corpora lutea) and prolonged menstrual cycles. Reversibility after discontinuation was observed. Human data are lacking; however, due to RANKL's role in reproductive processes (e.g., ovulation, implantation), there is a potential for reduced fertility in women of childbearing potential. Effects on male fertility are unknown. |